Opexa Therapeutics to Present at BIO 2007 Business Forum
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that the Company will be presenting in the Business Forum at BIO 2007, the Biotechnology Industry Organization’s Annual International Convention being held at the Boston Convention & Exhibition Center from May 6-9, 2007. Brian Newsom, senior director of project management at Opexa, will be giving the Company’s corporate presentation on Wednesday, May 9th, at 10:45 a.m. Eastern Time in Room E.
The BIO Business Forum is the largest partnering and networking program in the industry. It is a program that offers pharmaceutical companies, biotechnology companies, academic research institutions and investors from around the world the unique opportunity to gather in one place at one time to learn about each other and to meet one-on-one to discuss business opportunities of mutual interest.
The Biotechnology Industry Organization (BIO), founded in 1993, is a nonprofit association that represents more than 1,100 biotechnology companies, state and international affiliates, and related organizations. The BIO International Convention offers attendees an opportunity to meet with every key player in the biotechnology industry. Program participants include researchers, academia, entrepreneurs, venture capitalists, and others who will soon be recognized for their vision and achievement.
About Opexa Therapeutics
Opexa Therapeutics develops and commercializes cell therapies to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin(TM), a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for diabetes mellitus. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.